FR3107648B1 - conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie - Google Patents

conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie Download PDF

Info

Publication number
FR3107648B1
FR3107648B1 FR2001974A FR2001974A FR3107648B1 FR 3107648 B1 FR3107648 B1 FR 3107648B1 FR 2001974 A FR2001974 A FR 2001974A FR 2001974 A FR2001974 A FR 2001974A FR 3107648 B1 FR3107648 B1 FR 3107648B1
Authority
FR
France
Prior art keywords
antibody
therapy
drug conjugates
conjugates
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2001974A
Other languages
English (en)
French (fr)
Other versions
FR3107648A1 (fr
Inventor
Ludovic Juen
Christine Baltus
Audrey Desgranges
Antoine Touzé
Thibault Kervarrec
Valérie Leblond
Mahtab Samimi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mcsaf Inside Oncology Fr
Original Assignee
Mc Saf
Centre Hospitalier Regional Universitaire de Tours
Universite de Tours
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2001974A priority Critical patent/FR3107648B1/fr
Application filed by Mc Saf, Centre Hospitalier Regional Universitaire de Tours, Universite de Tours filed Critical Mc Saf
Priority to PCT/FR2021/050332 priority patent/WO2021170961A1/fr
Priority to US17/802,274 priority patent/US20230144142A1/en
Priority to EP21714002.9A priority patent/EP4110405A1/fr
Priority to JP2022552310A priority patent/JP2023515845A/ja
Priority to CA3166699A priority patent/CA3166699A1/fr
Priority to CN202180017269.9A priority patent/CN115515642A/zh
Priority to AU2021227413A priority patent/AU2021227413A1/en
Publication of FR3107648A1 publication Critical patent/FR3107648A1/fr
Application granted granted Critical
Publication of FR3107648B1 publication Critical patent/FR3107648B1/fr
Priority to US18/333,261 priority patent/US20230405140A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR2001974A 2020-02-27 2020-02-27 conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie Active FR3107648B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR2001974A FR3107648B1 (fr) 2020-02-27 2020-02-27 conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie
US17/802,274 US20230144142A1 (en) 2020-02-27 2021-02-26 Anti-cd56 antibody-drug conjugates and their use in therapy
EP21714002.9A EP4110405A1 (fr) 2020-02-27 2021-02-26 Conjugués anticorps-médicament anti-cd56 et leur utilisation en thérapie
JP2022552310A JP2023515845A (ja) 2020-02-27 2021-02-26 抗－ｃｄ５６抗体－薬物複合体およびその治療での使用
PCT/FR2021/050332 WO2021170961A1 (fr) 2020-02-27 2021-02-26 Conjugués anticorps-médicament anti-cd56 et leur utilisation en thérapie
CA3166699A CA3166699A1 (fr) 2020-02-27 2021-02-26 Conjugues anticorps-medicament anti-cd56 et leur utilisation en therapie
CN202180017269.9A CN115515642A (zh) 2020-02-27 2021-02-26 抗cd56抗体-药物偶联物及其在治疗中的用途
AU2021227413A AU2021227413A1 (en) 2020-02-27 2021-02-26 Anti-CD56 antibody-drug conjugates and their use in therapy
US18/333,261 US20230405140A1 (en) 2020-02-27 2023-06-12 Anti-cd56 antibody-drug conjugates and their use in therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2001974A FR3107648B1 (fr) 2020-02-27 2020-02-27 conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie
FR2001974 2020-02-27

Publications (2)

Publication Number Publication Date
FR3107648A1 FR3107648A1 (fr) 2021-09-03
FR3107648B1 true FR3107648B1 (fr) 2022-03-18

Family

ID=71894885

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2001974A Active FR3107648B1 (fr) 2020-02-27 2020-02-27 conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie

Country Status (8)

Country Link
US (2) US20230144142A1 (https=)
EP (1) EP4110405A1 (https=)
JP (1) JP2023515845A (https=)
CN (1) CN115515642A (https=)
AU (1) AU2021227413A1 (https=)
CA (1) CA3166699A1 (https=)
FR (1) FR3107648B1 (https=)
WO (1) WO2021170961A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3096259B1 (fr) * 2019-05-20 2023-12-15 Mc Saf conjugués anticorps-médicament et leur utilisation en thérapie
FR3131835B1 (fr) * 2022-01-17 2025-11-21 Mc Saf Procédé de préparation de conjugués anticorps-médicament
FR3131836B1 (fr) * 2022-01-17 2025-05-23 Mc Saf Conjugués anticorps-médicament pour utilisation thérapeutique
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025149947A1 (en) * 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640572B (zh) * 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物，偶联方法，及其用途
WO2013177062A2 (en) * 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
FR3008408B1 (fr) * 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
US10548987B2 (en) 2015-07-31 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting CD56-positive tumors
CN107744592B (zh) * 2017-09-15 2020-04-28 四川大学 抗cd56抗体与海兔毒素偶联复合物及其制备方法和用途
CN107715119B (zh) * 2017-09-15 2020-11-10 四川大学 抗cd56抗体与多卡霉素偶联复合物及其制备方法和用途
SG11202006510XA (en) * 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof

Also Published As

Publication number Publication date
US20230144142A1 (en) 2023-05-11
WO2021170961A1 (fr) 2021-09-02
FR3107648A1 (fr) 2021-09-03
EP4110405A1 (fr) 2023-01-04
AU2021227413A1 (en) 2022-10-20
JP2023515845A (ja) 2023-04-14
US20230405140A1 (en) 2023-12-21
CA3166699A1 (fr) 2021-09-02
CN115515642A (zh) 2022-12-23

Similar Documents

Publication Publication Date Title
FR3107648B1 (fr) conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie
PH12020551923A1 (en) Methods and compositions for treating cancer
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
MX2021007790A (es) Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
FR3096259B1 (fr) conjugués anticorps-médicament et leur utilisation en thérapie
EA201891607A1 (ru) Axl-специфичные конъюгаты антитело-лекарственное средство для лечения злокачественных новообразований
MA43000B1 (fr) Polythérapie pour le traitement de tumeurs malignes
MA42999B1 (fr) Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë
NO20054988D0 (no) Preparater og metoder for behandling av cancer
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
MX2020006654A (es) Métodos intraductales de tratamiento de trastornos de mama.
SG10201811480WA (en) Therapeutic compounds and compositions
MX2022005411A (es) COMPUESTOS DE UNIÓN A IL-2RßYC.
ZA201907225B (en) Treatment of her2 positive cancers
PH12022550141A1 (en) Immunomodulatory antibodies and methods of use thereof
BR112021025699A2 (pt) Anticorpos anti-mesotelina e imunoconjugados dos mesmos
MX2022013402A (es) Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y folfiri.
MA33091B1 (fr) Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
MX2024002069A (es) Anticuerpos anti-hla-g.
MX2024005484A (es) Combinaciones antineoplásicas que contienen conjugados de anticuerpo-fármaco anti-ceacam5 y anticuerpos anti-vegfr-2.
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
WO2021081457A3 (en) Methods and agents for enhancing t cell therapies
MX2024010916A (es) Conjugados anticuerpo-farmaco que comprenden agonistas de sting, combinaciones y metodos de uso.
MX2025004144A (es) Anticuerpo anti-gucy2c y usos del mismo

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210903

PLFP Fee payment

Year of fee payment: 3

TP Transmission of property

Owner name: MC SAF, FR

Effective date: 20211014

TP Transmission of property

Owner name: MCSAF INSIDE ONCOLOGY, FR

Effective date: 20220822

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7